AIA Group Ltd Sells 8,842 Shares of Pfizer Inc. (NYSE:PFE)

AIA Group Ltd decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 10.0% during the fourth quarter, Holdings Channel reports. The fund owned 79,196 shares of the biopharmaceutical company’s stock after selling 8,842 shares during the period. AIA Group Ltd’s holdings in Pfizer were worth $2,280,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Front Street Capital Management Inc. grew its holdings in shares of Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 215 shares during the period. Castleview Partners LLC grew its stake in shares of Pfizer by 2.4% in the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 287 shares during the last quarter. United Bank grew its stake in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after buying an additional 290 shares during the last quarter. Compton Capital Management Inc. RI grew its stake in shares of Pfizer by 0.5% in the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock worth $3,308,000 after buying an additional 300 shares during the last quarter. Finally, GHP Investment Advisors Inc. grew its stake in shares of Pfizer by 2.4% in the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after buying an additional 307 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several recent research reports. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $36.88.

Pfizer Price Performance

NYSE PFE opened at $25.41 on Friday. The stock has a market capitalization of $143.89 billion, a price-to-earnings ratio of 70.51, a PEG ratio of 1.15 and a beta of 0.61. The business’s fifty day moving average price is $27.14 and its 200-day moving average price is $28.74. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.